Haleon Enters US OTC Erectile Dysfunction Race With Futura Deal

Haleon steps into the US OTC erectile dysfunction market with a commercialization deal for Futura's drug-free MED3000 gel, recently approved by the FDA as a de novo medical device. 

• Source: Shutterstock

Haleon plc has made the first move into the US’s new OTC erectile dysfunction (ED) category with a multimillion-dollar deal for Futura Medical plc’s non-prescription MED3000 gel.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from United States

More from North America